Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Tom Wilkinson @ProfWilko
Just heard the amazing news that the UNIVERSAL respiratory virus study has recruited its 500 subject- amazing progress and halfway to target Many congratulations to all our clinical teams
@UoS_Medicine @SouthamptonBRC @SouthamptonCTU
https://twitter.com/ProfWilko/status/1733150775168114688
Mani seems to be referring to https://www.isrctn.com/ISRCTN49183956 which is sporadically updated and as far as im aware has always shown as no longer recruiting.
Dundee Hospital is also part of recruiting for the UNIVERSAL study, and the below info indicates they are in still active in recruitment up untill end of Jan 2024
https://discovery.dundee.ac.uk/en/projects/understanding-infection-viral-exacerbation-and-respiratory-sympto
I know this inst the most accurate way of working things out as recruits will fluctuate during seasons but first subject was recruited on 1st September 2022 and reached 500th subject on 8th December 2023. so it took 15 months to recruit 500 subjects which works out 33.333 recruits per month so based on a a rate of 33.33 recruits per month, we could be looking at March 2025 for recruitment to be completed.
Lets hope the recruitment process has been refined and target is reached way sooner.
@jonnyboy33 I dont think the date there is accurate as only last Friday Prof Tom Wilkinson confirmed 500th subject was recruited for the study and the target is 1000 subjects.
https://twitter.com/ProfWilko/status/1733150775168114688
Https://www.isrctn.com/ISRCTN49183956
If you check the bottom editorial notes, you can see it was updated on 14/11/23:
14/11/2023: The overall end date was changed from 17/06/2024 to 17/02/2025.
MrCosts - "Rampers" have quietly dispersed or changed tune. "De-rampers" were proven right . All other investors in between are aware of the reality that this share is in the mud right now. Those who could afford have sold and looked to make a recovery elsewhere and moved on, others who cant afford that have nothing else to do but wait this out and hope that a situation arises where we can at minimum recover our initial investment, close to it or best case scenario make a profit.
The company is small, the company is far from perfect, most investors expect comms that doesn't align with company's comms strategy, there have been mistakes, oversights, slow progress. We all know this, there isn't much we can do except hold on and discuss any updates that have either been found by investors or issued from the company.
The SP is currently 8.75p if it goes to 0p it doesn't make a difference to most that have been holding long term. We either stay in the mud or make progress. You have every right to but complaining on here is not going to achieve anything.
Status: Active
Effective start/end date
1/09/23 → 31/01/24
https://discovery.dundee.ac.uk/en/projects/understanding-infection-viral-exacerbation-and-respiratory-sympto
The below article and quote is from 12th Jan 2023.
“ Due to the winter pressures, Southampton has had a flying start and we are already planning our first read out, which will inform the design of interventional studies, which could launch later this year. Our team of research nurses and doctors, with support from UHS clinical teams, is organised by the Southampton Clinical Trials Unit which is developing a global reputation for expertise in respiratory studies. Although there is no drug involved as yet, the project is funded by close collaboration with industry partners, and we are bringing together a unique consortium of companies willing to work pre-competitively to understand more about this challenge to health.”
https://generic.wordpress.soton.ac.uk/medicallyspeaking/2023/01/12/using-our-expertise-to-help-ease-winter-pressures/
DocD, the New Years communication from RM which I'm sure you have already read is the only recent thing we have to get an idea as to what the company's "absolute focus" will be going forward. To me its quite clear they are looking to capitalise on the broad-spectrum antiviral properties of SNG001 against RVIs, how this will be achieved is yet to be seen.
"As it stands today, there are no broad-spectrum antivirals approved for use in patients with severe viral lung infections who are at increased risk of progressing to severe disease or death, and this is in the context of more than 3 million people a year being hospitalised due to these infections in the US alone. It is then perhaps not surprising that this also means there is no precedent for a broad-spectrum antiviral clinical development programme. Designing and determining a clinical pathway for this approach is complex, as there are multiple viruses being targeted for different high-risk patient groups.
This is our absolute focus. The Synairgen team, and our partners and advisors, have been working relentlessly to identify the optimal clinical development programme to confirm the signals we have seen, and investigate SNG001 against this wide spectrum of respiratory viruses."
I am unsure as to how recent the link has been updated but Google indicates 7 days ago.
“I specialise in capital markets and M&A, with a focus on the natural resources and healthcare sectors.”
“Advising Synairgen on several secondary placings.”
https://www.fladgate.com/our-team/nigel-gordon
Interesting to me that we are on the radar of UK’s Department of International Trade, their Twitter bio reads: “DIT helps businesses export, drives inward and outward investment, negotiates market access and trade deals and champions free trade”
We are delighted to have been selected as a UK Life Sciences #Innovator 2023 by @tradegovuk, as part of the @Arab_Health Exhibition!
More details can be found here: eu.eventscloud.com/website/9999/
#LSI2023 #ArabHealth2023 #UKInnovation
https://twitter.com/synairgenplc/status/1620393612226998272
https://youtu.be/o1GkB_RZzrA
Full podcast ^
https://twitter.com/synairgenplc/status/1597579747210526720
Host Directed, our new series exploring the need for new types of antivirals to treat severe respiratory infections, @ProfWilko & Vicki Tear discuss how antiviral agents work and potential benefits of broad-spectrum antivirals
Synairgen is mentioned in the section Conflict of interest: "TC has received consultancy fees from Biofire diagnostics LLC, BioMerieux, Synairgen research Ltd, Randox laboratories Ltd and Cidara therapeutics.".
TC I assume is Tristan W. Clark.
From the same paragraph:
"TC has been a member of advisory boards for Roche and Janssen and has received reimbursement for these. TC is member of two independent data monitoring committees for trials sponsored by Roche. TC has previously acted as the UK chief investigator for trials sponsored by Janssen. TC is currently a member of the NHSE COVID-19 Testing Technologies Oversight Group and the NHSE COVID-19 Technologies Validation Group. JS is a founding director, CEO, employee, and shareholder in TopMD Precision Medicine Ltd. "
DocD, you say Synairgen is not in the business of " comprehending how and why some people's lungs are unable to defend themselves"
Ofcourse they are, how would you expect them to produce a treatment?
Not sure if you saw but user cl2201 pointed out earlier the striking similarity in thr statement from the job post and https://www.synairgen.com/about "Understanding how and why some people’s lungs are unable to defend themselves has been at the heart of the Synairgen story for nearly 50 years."
Few mentions of STRIVE platform trial, can someone please provide a link or explanation what this trial is?
I’ve had google and I can’t pinpoint exactly which trial is being referred to. Thanks and apologies if I missed a explanation or l link that’s already been posted.